Managers / Q2 2022 · view latest →
Aquilo Capital Management, LLC
CIK 0001591986 · ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO, CA, 94129 · 415-635-0140
Summary
Aquilo Capital Management, LLC reported $293M in U.S.-listed holdings across 13 positions for Q2 2022.
Its largest position, ARWR, represents 14.4% of the portfolio.
Compared with Q1 2022, the fund opened 0 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 59.6% · $175M
- ETP · 19.0% · $56M
- Other · 15.9% · $46M
- ADR · 5.5% · $16M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF TR | SOLD OUT | −350.0K | 0 | −$158M | $0 |
| XBISPDR S&P BIOTECH ETF TR | TRIMMED | −1.25M | 750.0K | −$124M | $56M |
| FDMT4D MOLECULAR THERAPEUTICS IN | TRIMMED | −893.9K | 861.6K | −$21M | $6M |
| GMABGENMAB A/S | ADDED | +47.3K | 214.8K | +$920,000 | $7M |
| MERUS N V | ADDED | +215.6K | 1.48M | +$87,000 | $33M |
| ARWRARROWHEAD PHARMACEUTICALS IN | ADDED | +151.1K | 1.20M | −$6M | $42M |
| AMRYT PHARMA PLC | ADDED | +226.7K | 1.87M | −$515,000 | $13M |
| ARVNARVINAS INC | ADDED | +76.5K | 771.7K | −$14M | $32M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2022
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARWRARROWHEAD PHARMACEUTICALS INhistory → | COM | 14.40% | $42M | 1.20M |
| 2 | BLUEPRINT MEDICINES CORP | COM | 12.35% | $36M | 716.5K |
| 3 | MERUS N V | COM | 11.41% | $33M | 1.48M |
| 4 | ARVNARVINAS INChistory → | COM | 11.08% | $32M | 771.7K |
| 5 | RGNXREGENXBIO INChistory → | COM | 9.84% | $29M | 1.17M |
| 6 | QUREUNIQURE NVhistory → | SHS | 6.18% | $18M | 971.5K |
| 7 | AMRYT PHARMA PLC | SPONSORED ADS | 4.45% | $13M | 1.87M |
| 8 | ARGXARGENX SEhistory → | SPONSORED ADR | 3.10% | $9M | 24.0K |
| 9 | PIERIS PHARMACEUTICALS INC | COM | 2.38% | $7M | 3.74M |
| 10 | GMABGENMAB A/Shistory → | SPONSORED ADS | 2.38% | $7M | 214.8K |
| 11 | FDMT4D MOLECULAR THERAPEUTICS INhistory → | COM | 2.05% | $6M | 861.6K |
| 12 | SPROSPERO THERAPEUTICS INChistory → | COM | 1.35% | $4M | 5.32M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2025 | $0 | 1 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $0 | 1 | Aug 6, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $56M | 13 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $66M | 15 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $132M | 14 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $104M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $133M | 10 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $160M | 10 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $110M | 12 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $180M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $241M | 12 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $266M | 13 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $277M | 15 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $293M | 13 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $680M | 14 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $882M | 14 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $551M | 14 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $385M | 15 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $553M | 17 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $481M | 17 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $945M | 17 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $496M | 14 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $257M | 14 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $266M | 12 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 11 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $288M | 13 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $226M | 14 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.